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Ten years ago we established O-6-methylguanine-DNAmethyl-
transferase (MGMT) gene promoter methylation as the first pre-
dictive marker in neuro-oncology, and the strongest prognostic
factor for treatment outcome in patients with newly diagnosed
glioblastoma (GBM). But rather than embracing a marker that
allows identification and selection of patients likely to derive
some benefit from the addition of alkylating agent chemother-
apy, we have been challenging the validity of the findings, are
still striving for the one perfect molecular test, and are treating
the majority of patients with temozolomide (TMZ) chemother-
apy irrespective of the tumor’s MGMT promoter status. Aren′t
the data convincing enough, or is it because of the lack of effec-
tive alternative treatments to be offered to patients with an
unmethylated MGMT promoter?
Following a large body of mechanistic evidence for the role
of MGMT in repairing lesions of alkylating agents, MGMTexpres-
sion was advanced as a resistance factor in glioma in the
1990s. Subsequently, seminal work by Esteller and colleagues1
demonstrated a correlation with promoter methylation of the
MGMT gene in an analysis of samples from patients in Spain
treated with chemotherapy comprising the alkylating agent
carmustine (BCNU). We confirmed this observation in an un-
planned analysis of patients treated within our phase II trial
with upfront TMZ.2 Finally, in 2005, our retrospective analysis
of prospectively treated patients within a randomized phase
III trial demonstrated a clear predictive value of MGMT promot-
er methylation status.3 Since then, numerous additional trials
have consistently demonstrated the prognostic effect of the
MGMT status, but as all patients are now receiving upfront
TMZ chemotherapy, the predictive value could not be evaluated
again. The one exception is elderly glioblastoma patients in
whom the relative benefit of adding chemotherapy is of lesser
magnitude. Two randomized trials compared single-agent TMZ
chemotherapy versus radiotherapy (RT).4,5 In this more fragile
patient population it was shown that treating MGMT unmethy-
lated tumors with TMZ was detrimental, while patients with
methylated tumors fared best if treated with TMZ (even in
the absence of RT). These 2 trials confirm the predictive value
of the MGMT status. Together, the data allow the conclusion
that alkylating agent chemotherapy is of marginal benefit, if
any, for patients with MGMT unmethylated GBM.
By continuing to treat the majority of MGMT unmethylated
patients with TMZ, we are missing an opportunity to do better.
Innovative treatment approaches with novel agents in combi-
nation with RT may provide a better chance for improved out-
come than adhering to the use of an agent with marginal
activity. From the patient’s point of view, it may be perceived
as “wasting the last opportunity” to try a potentially efficacious
new agent. Clearly, this patient population would benefit most
from drugs with other mechanisms of action. To date, only a
few trials have selected patients and assigned treatments ac-
cording to MGMT promoter methylation status.6–9
Adding a new drug or agent on top of the previously estab-
lished combinedmodality regimenmay cause undue toxicity or
drug interaction, thus requiring dose reduction and treatment
with potentially subtherapeutic doses. As an example, the ad-
dition of polyglutamated paclitaxel to the combination of TMZ/
RT led to early discontinuation due to prohibitive toxicity,10
but this resulted in a follow-up trial in MGMT unmethylated
patients only, omitting TMZ during RT (www.clinicaltrials.gov:
NCT01402063). Still, patients with an unmethylated MGMT pro-
moter are in greatest need of improved treatments and may
benefit from the opportunity to replace TMZ by novel agents.
In a randomized European Organisation for Research and Treat-
ment of Cancer (EORTC) trial for patients with an unmethylated
MGMT promoter only, temsirolimus was combined with RT
followed by temsirolimus maintenance and compared with
standard TMZ/RT followed by TMZ.8 Similarly, Herrlinger and
colleagues9 randomized patients with an unmethylated
MGMT promoter to either standard TMZ/RT followed by TMZ or
RT combined with irinotecan and bevacizumab followed by
maintenance irinotecan/bevacizumab. Although both trials
failed to show improved outcome compared with the standard,
it is important to note that dropping TMZ was not detrimental
(Table 1).
Treatment selection according to a molecular marker is inti-
mately dependent on the validity and reproducibility of the mo-
lecular test. Standardizing the MGMTassay and determining the
# The Author(s) 2015. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved.
For permissions, please e-mail: journals.permissions@oup.com.
Neuro-Oncology
Neuro-Oncology 17(11), 1425–1427, 2015
doi:10.1093/neuonc/nov198
Advance Access date 15 September 2015
1425
Downloaded from https://academic.oup.com/neuro-oncology/article-abstract/17/11/1425/1041691
by University of Zurich user
on 08 August 2018
optimal cutoff for outcome prediction have been a challenge. It
is obvious that choice of methodology and quantity and quality
of the sample may yield different limits of detection and levels
of precision for prediction. Of note, unlike amutation that is pre-
sent or absent, promoter methylation creates a pattern recog-
nized by so-called methyl-binding proteins, which are relevant
for inhibition of expression. These patterns are identified by dif-
ferent means depending on the methodology. This can result in
some discrepancies of classification that mostly affect samples
with incomplete methylation. As with any test in medicine,
however, appropriate validation is required, including but not
limited to reproducibility and association with outcome in an in-
dependent prospective cohort. Prospective testing in the trials
reported earlier has been performed centrally using a quantita-
tive methylation-specific PCR assay that is commercially avail-
able.11 In this assay the technical cutoff between methylated
and unmethylated was set at the nadir of the bimodal distribu-
tion of the methylated MGMTmeasured (ratio with a normaliz-
ing gene) in a large population of samples.6 Evidently, there is a
gray zone around the cutoff that can be approximated by a
confidence interval. In 2 of the trials dropping TMZ,8,9 the
lower boundary of the 95% CI was used to select unmethylated
patients (cutoff with a “safety margin”) in order to avoid with-
holding TMZ from a patient who could potentially profit. The
challenges of MGMT testing have been reviewed extensively
elsewhere.12
Additional biomarkers are required for appropriate testing of
new targeted drugs allowing for selective enrichment of the
potentially sensitive patient population. The frequency of a
potentially druggable target, however, may be so low (eg, 3%
for fibroblast growth factor receptor 3–transforming acidic
coiled-coil protein 3 fusions13) that conducting prospective
and controlled clinical trials is practically impossible. Quality as-
surance and the paucity of material available in the brain re-
quire platforms that will provide an array of biomarkers rather
than individual tests.
Patients with unmethylated GBM are in need of better treat-
ments. This population not only offers the opportunity to test
novel treatments but actually requires—more than other
patients—that they be offered innovative therapies right from
the diagnosis of GBM. The extended experience of the predictive
value of the MGMT status in GBM and the reassuring first results
from trials selecting patients with unmethylated MGMT for ex-
perimental therapy omitting TMZ provide sufficient confidence
for such an adapted trial design. Recruiting patients according
to their MGMT status opens opportunities for innovative new
therapies not limited by the treatment scheme of TMZ and its
toxicity. This will allow us to focus on new drugs that need to be
developed together with their corresponding biomarkers.
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